No new drug, just watching: kidney transplant patients monitored after experimental therapy

NCT ID NCT05106387

Recruiting now Knowledge-focused Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study is a long-term follow-up for 20 people with chronic kidney disease who received an experimental drug called vonsetamig and then had a kidney transplant in an earlier study. No new treatment is given here. Researchers will track how the drug affects the body and monitor transplant outcomes, such as organ rejection and side effects, for up to 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (CKD)

Contacts and locations

Locations

Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Comprehensive Transplant Center
RECRUITING

Chicago, Illinois, 60611, United States
Connie Frank Transplant Center at UCSF
RECRUITING

San Francisco, California, 94143, United States
John Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21224, United States
New York University Langone Health
COMPLETED

New York, New York, 10016, United States
Penn Transplant Institute
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of California Irvine
RECRUITING

Orange, California, 92868, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
Yale University of Medicine
COMPLETED

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.